Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 versus trastuzumab + pertuzumab + docetaxel as first-line treatment for HER2-positive recurrent or metastatic breast cancer
CTR20261431Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab repodatecan in breast cancer, sponsored by Kanion Pharmaceutical. Started May 2026; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261431.